http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012124985-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 |
| filingDate | 2010-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012124985-A |
| titleOfInvention | DOSAGE FORM FOR COMBINATION OF HGH AND RHIGF-1 |
| abstract | 1. A pharmaceutical composition comprising IGF-1 and GH and is an aggregation prevention agent; a buffer; a surfactant; optionally a preservative; and optionally a tonicity modifier or excipient, wherein the aggregation preventive agent is present in the composition in a concentration of at least about 80 mM. The pharmaceutical composition according to claim 1, wherein the aggregation preventing agent is arginine (arginine ion) or lysine. The pharmaceutical composition according to claim 2, wherein the aggregation preventing agent is arginine at a concentration of about 80-200 mm, preferably about 100-150 mm. The pharmaceutical composition according to any one of claims 1-3, wherein the buffer is selected from histidine, succinate or citrate in a concentration of about 1-50 mM, preferably about 10-20 mM. 5. The pharmaceutical composition according to claim 1, wherein the surfactant is a nonionic surfactant. The pharmaceutical composition of claim 5, wherein the non-ionic surfactant is Polysorbate 20 at a concentration of about 0.1-0.3% by weight, preferably about 0.2% by weight. The pharmaceutical composition of claim 5, wherein the non-ionic surfactant is Poloxamer 188 at a concentration of about 0.1-0.5% by weight, preferably about 0.3% .8. The pharmaceutical composition of claim 1, wherein the tonicity modifier is sodium chloride. The pharmaceutical composition of claim 1, wherein the excipient is mannitol and / or sucrose. Pharmaceutical Composition |
| priorityDate | 2009-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.